|
1
|
Wei WI and Sham JS: Nasopharyngeal
carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lo KW, Chung GT and To KF: Deciphering the
molecular genetic basis of NPC through molecular, cytogenetic, and
epigenetic approaches. Semin Cancer Biol. 22:79–86. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feng XP, Yi H, Li MY, Li XH, Yi B, Zhang
PF, Li C, Peng F, Tang CE, Li JL, et al: Identification of
biomarkers for predicting nasopharyngeal carcinoma response to
radiotherapy by proteomics. Cancer Res. 70:3450–3462. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu
LZ, Sun Y, Lin AH, Liu MZ and Ma J: How does intensity-modulated
radiotherapy versus conventional two-dimensional radiotherapy
influence the treatment results in nasopharyngeal carcinoma
patients? Int J Radiat Oncol Biol Phys. 80:661–668. 2011.
View Article : Google Scholar
|
|
5
|
Gupta AK, McKenna WG, Weber CN, Feldman
MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ,
Cerniglia GJ, et al: Local recurrence in head and neck cancer:
relationship to radiation resistance and signal transduction. Clin
Cancer Res. 8:885–892. 2002.PubMed/NCBI
|
|
6
|
Kim VN, Han J and Siomi MC: Biogenesis of
small RNAs in animals. Nat Rev Mol Cell Biol. 10:126–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Frankel LB, Wen J, Lees M, Høyer-Hansen M,
Farkas T, Krogh A, Jäättelä M and Lund AH: microRNA-101 is a potent
inhibitor of autophagy. EMBO J. 30:4628–4641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: microRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O’Day E and Lal A: MicroRNAs and their
target gene networks in breast cancer. Breast Cancer Res.
12:2012010. View
Article : Google Scholar
|
|
11
|
Zheng J, Deng J, Xiao M, Yang L, Zhang L,
You Y, Hu M, Li N, Wu H, Li W, et al: A sequence polymorphism in
miR-608 predicts recurrence after radiotherapy for nasopharyngeal
carcinoma. Cancer Res. 73:5151–5162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang JX, Qian D, Wang FW, Liao DZ, Wei
JH, Tong ZT, Fu J, Huang XX, Liao YJ, Deng HX, et al: microRNA-29c
enhances the sensitivities of human nasopharyngeal carcinoma to
cisplatin-based chemotherapy and radiotherapy. Cancer Lett.
329:91–98. 2013. View Article : Google Scholar
|
|
13
|
He XP, Shao Y, Li XL, Xu W, Chen GS, Sun
HH, Xu HC, Xu X, Tang D, Zheng XF, et al: Downregulation of miR-101
in gastric cancer correlates with cyclooxygenase-2 overexpression
and tumor growth. FEBS J. 279:4201–4212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao
Y, Lv Y and Song Y: miR-101 and Mcl-1 in non-small-cell lung
cancer: expression profile and clinical significance. Med Oncol.
29:1681–1686. 2012. View Article : Google Scholar
|
|
15
|
Schee K, Boye K, Abrahamsen TW, Fodstad Ø
and Flatmark K: Clinical relevance of microRNA miR-21, miR-31,
miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC
Cancer. 12:5052012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang R, Wang HB, Hao CJ, Cui Y, Han XC, Hu
Y, Li FF, Xia HF and Ma X: miR-101 is involved in human breast
carcinogenesis by targeting Stathmin1. PLoS One. 7:e461732012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Han C, Zhu H, Song K and Wu T:
miR-101 inhibits cholangiocarcinoma angiogenesis through targeting
vascular endothelial growth factor (VEGF). Am J Pathol.
182:1629–1639. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen S, Wang H, Ng WL, Curran WJ and Wang
Y: Radiosensitizing effects of ectopic miR-101 on non-small-cell
lung cancer cells depend on the endogenous miR-101 level. Int J
Radiat Oncol Biol Phys. 81:1524–1529. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Green LM, Reade JL and Ware CF: Rapid
colorimetric assay for cell viability: application to the
quantitation of cytotoxic and growth inhibitory lymphokines. J
Immunol Methods. 70:257–268. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie G, Zhan J, Tian Y, Liu Y, Chen Z, Ren
C, Sun Q, Lian J, Chen L, Ruan J, et al: Mammosphere cells from
high-passage MCF7 cell line show variable loss of tumorigenicity
and radioresistance. Cancer Lett. 316:53–61. 2012. View Article : Google Scholar
|
|
21
|
Mah LJ, El-Osta A and Karagiannis TC:
gammaH2AX: a sensitive molecular marker of DNA damage and repair.
Leukemia. 24:679–686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kong W, He L, Richards EJ, Challa S, Xu
CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY and
Cheng JQ: Upregulation of miRNA-155 promotes tumour angiogenesis by
targeting VHL and is associated with poor prognosis and
triple-negative breast cancer. Oncogene. 33:679–689. 2014.
View Article : Google Scholar :
|
|
23
|
Oue N, Anami K, Schetter AJ, Moehler M,
Okayama H, Khan MA, Bowman ED, Mueller A, Schad A, Shimomura M, et
al: High miR-21 expression from FFPE tissues is associated with
poor survival and response to adjuvant chemotherapy in colon
cancer. Int J Cancer. 134:1926–1934. 2014. View Article : Google Scholar
|
|
24
|
Schliekelman MJ, Gibbons DL, Faca VM,
Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn
YH, et al: Targets of the tumor suppressor miR-200 in regulation of
the epithelial-mesenchymal transition in cancer. Cancer Res.
71:7670–7682. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu X, Guo J, Zheng L, Li C, Zheng TM,
Tanyi JL, Liang S, Benedetto C, Mitidieri M, Katsaros D, Zhao X,
Zhang Y, Huang Q and Zhang L: The heterochronic microRNA let-7
inhibits cell motility by regulating the genes in the actin
cytoskeleton pathway in breast cancer. Mol Cancer Res. 11:240–250.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choi AM, Ryter SW and Levine B: Autophagy
in human health and disease. N Engl J Med. 368:651–662. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Y, Yin W and Zhu X: Blocked autophagy
enhances radiosensitivity of nasopharyngeal carcinoma cell line
CNE-2 in vitro. Acta Otolaryngol. 134:105–110. 2014. View Article : Google Scholar
|
|
28
|
Luo C, Merz PR, Chen Y, Dickes E, Pscherer
A, Schadendorf D and Eichmüller SB: miR-101 inhibits melanoma cell
invasion and proliferation by targeting MITF and EZH2. Cancer Lett.
341:240–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan D, Ng WL, Zhang X, Wang P, Zhang Z, Mo
YY, Mao H, Hao C, Olson JJ, Curran WJ and Wang Y: Targeting
DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS
One. 5:e113972010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wik E, Birkeland E, Trovik J, Werner HM,
Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson
IM, et al: High phospho-Stathmin(Serine38) expression identifies
aggressive endometrial cancer and suggests an association with PI3K
inhibition. Clin Cancer Res. 19:2331–2341. 2013. View Article : Google Scholar : PubMed/NCBI
|
